Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis

Marquardt, Stephan; Solanki, Manish; Spitschak, Alf; Vera, Julio; Pützer, Brigitte M.

doi:10.1016/j.semcancer.2018.06.006

Cited by 76 publications

(58 citation statements)

References 282 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results have been observed in glioma cells, breast cancer cells (147), not small-cells lung carcinoma (NSCLC), PDAC, and others (147)(148)(149)(150). The presence of CD47 in AML was also associated with a high self-renewal potential of cancer stem cells and with low patient survival (151,152). CD47 overexpression also correlates with poor prognosis in head and neck squamous cell carcinoma, melanoma, and osteosarcoma (153)(154)(155)(156).…”

Section: Impaired Dcs Recruitment: Ccl4 Inhibitionsupporting

confidence: 73%

WNT Signaling in Tumors: The Way to Evade Drugs and Immunity

et al. 2019

View full text Add to dashboard Cite

WNT/β-catenin signaling is involved in many physiological processes. Its implication in embryonic development, cell migration, and polarization has been shown. Nevertheless, alterations in this signaling have also been related with pathological events such as sustaining and proliferating the cancer stem cell (CSC) subset present in the tumor bulk. Related with this, WNT signaling has been associated with the maintenance, expansion, and epithelial-mesenchymal transition of stem cells, and furthermore with two distinctive features of this tumor population: therapeutic resistance (MDR, multidrug resistance) and immune escape. These mechanisms are developed and maintained by WNT activation through the transcriptional control of the genes involved in such processes. This review focuses on the description of the best known WNT pathways and the molecules involved in them. Special attention is given to the WNT cascade proteins deregulated in tumors, which have a decisive role in tumor survival. Some of these proteins function as extrusion pumps that, in the course of chemotherapy, expel the drugs from the cells; others help the tumoral cells hide from the immune effector mechanisms. Among the WNT targets involved in drug resistance, the drug extrusion pump MDR-1 (P-GP, ABCB1) and the cell adhesion molecules from the CD44 family are highlighted. The chemokine CCL4 and the immune checkpoint proteins CD47 and PD-L1 are included in the list of WNT target molecules with a role in immunity escape. This pathway should be a main target in cancer therapy as WNT signaling activation is essential for tumor progression and survival, even in the presence of the anti-tumoral immune response and/or antineoplastic drugs. The appropriate design and combination of anti-tumoral strategies, based on the modulation of WNT mediators and/or protein targets, could negatively affect the growth of tumoral cells, improving the efficacy of these types of therapies.

show abstract

Section: Impaired Dcs Recruitment: Ccl4 Inhibitionsupporting

confidence: 73%

WNT Signaling in Tumors: The Way to Evade Drugs and Immunity

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Hypoxia is associated with therapy resistance in CSCs through activation of EMT genes (Lytle et al, ) and autophagy process (Dianat‐Moghadam et al, ). There is a direct relation between hypoxia and ECM composition, which plays a key function in the emergence of CSCs (Marquardt et al, ). Hypoxia‐inducible factor 1 (HIF‐1) and HIF‐2α are main of hypoxia response in cancers.…”

Section: Csc Targeting In Cancer Therapymentioning

confidence: 99%

“…Evaluation of the rate of expressions for related genes and protein signature in CSCs is reflective of their density in patient's tumor tissues (Marquardt et al, 2018). CD24, CD26, CD44, CD133, CD166, Poeta, Signori, & Fazio, 2018).…”

Section: Identification Of Cscsmentioning

confidence: 99%

Cancer stem cells (CSCs) in cancer progression and therapy

Najafi

Farhood

Mortezaee

2018

Journal Cellular Physiology

446

268

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are self‐renewable cell types that are identified in most types of liquid and solid cancers and contributed to tumor onset, expansion, resistance, recurrence, and metastasis after therapy. CSCs are identified from the expression of cell surface markers, which is tumor‐type dependent. The transition between CSCs with cancer cells and other non‐CSCs occurs in cancers, which is possibly under the control of signals from CSCs and tumor microenvironment (TME), including CSC niche. Cancer‐associated fibroblasts are among the most influential cells for promoting both differentiation of CSCs and dedifferentiation of non‐CSCs toward attaining a CSC‐like phenotype. WNT/β‐catenin, transforming growth factor‐β, Hedgehog, and Notch are important signals for maintaining self‐renewal in CSCs. An effective therapeutic strategy relies on targeting both CSCs and non‐CSCs to remove a possible chance of tumor relapse. There are multiple ways to target CSCs, including immunotherapy, hormone therapy, (mi)siRNA delivery, and gene knockout. Such approaches can be designed for suppressing CSC stemness, tumorigenic cues from TME, CSC extrinsic and/or intrinsic signaling, hypoxia or for promoting differentiation in the cells. Because of sharing a range of characteristics to normal stem/progenitor cells, CSCs must be targeted based on their unique markers and their preferential expression of antigens.

show abstract

“…In recent years, more attention has been given to genomic tools that explore biomarkers associated with prognosis prediction and targeted treatment [5,6]. However, these genomic technologies are expensive at present and more genomic information needs to be integrated due to the biological complexity of NSCLC [7].…”

Section: Introductionmentioning

confidence: 99%

Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer

Xue

2020

Bioscience Reports

View full text Add to dashboard Cite

Objectives: The purpose of the present study was to evaluate the prognostic value of a systemic immune-inflammation index (SII) and the relationship between SII and the effectiveness of postoperative treatment in patients with non-small cell lung cancer (NSCLC). Methods: A total of 538 patients diagnosed with NSCLC who had undergone curative surgery were retrospectively enrolled in the study. Clinicopathologic and laboratory variables were collected. SII was defined as neutrophil × platelet/lymphocyte counts. Both univariate and multivariate analyses were performed to analyze the prognostic value of these factors. Results: The preoperative SII level was associated with sex, smoking history, histological type, lesion type, resection type, pathological stage, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), fibrinogen and bone metastasis (P<0.05). The univariate and multivariate analyses revealed that SII was an independent prognostic factor for disease-free survival (DFS, P=0.033) and overall survival (OS, P=0.020). Furthermore, the prognostic value of SII was also verified regardless of the histological type and pathological stage. The subgroup analysis demonstrated that patients with a high SII may benefit from adjuvant therapy (P=0.024 for DFS and P=0.012 for OS). Conclusion: An increased preoperative SII may independently predict the poor DFS and OS in patients with resectable NSCLC. SII may help select NSCLC patients who might benefit from adjuvant chemotherapy.

show abstract

Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis

Cited by 76 publications

References 282 publications

WNT Signaling in Tumors: The Way to Evade Drugs and Immunity

WNT Signaling in Tumors: The Way to Evade Drugs and Immunity

Cancer stem cells (CSCs) in cancer progression and therapy

Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer

Contact Info

Product

Resources

About